Isoxanthohumol reduces neointimal hyperplasia through the apelin/AKT pathway.

The abnormal proliferation, migration, and inflammation of vascular smooth muscle cells (VSMCs) play crucial roles in the development of neointimal hyperplasia and restenosis. Exposure to inflammatory cytokines such as platelet-derived growth factor (PDGF)-BB and tumour necrosis factor-alpha (TNF-α) induces the transformation of contractile VSMCs into abnormal synthetic VSMCs. Isoxanthohumol (IXN) has significant anti-inflammatory, antiproliferative, and antimigratory effects. This study aimed to explore the therapeutic impact and regulatory mechanism of IXN in treating neointimal hyperplasia. The present findings indicate that IXN effectively hinders the abnormal proliferation, migration, and inflammation of VSMCs triggered by PDGF or TNF-α. This inhibition is primarily achieved through the modulation of the apelin/AKT or AKT pathway, respectively. In an in vivo model, IXN effectively reduced neointimal hyperplasia in denuded femoral arteries. These results suggest that IXN holds promise as a potential and innovative therapeutic candidate for the treatment of restenosis. Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.

Citation

Ting-Yu Chang, Mao-Shin Lin, Chin-Chuan Chen, Yann-Lii Leu, Shu-Huei Wang. Isoxanthohumol reduces neointimal hyperplasia through the apelin/AKT pathway. Biochimica et biophysica acta. Molecular basis of disease. 2024 Apr;1870(4):167099

Mesh Tags

Substances

PMID: 38428686

search → result